TRIMTECH Therapeutics raises £11m led by JJDC and BGF
This article covers TRIMTECH Therapeutics, a biotech startup, which has raised an additional £11m in a seed funding round, taking the total raised in the round to £35m. The funding will accelerate development of its proprietary small-molecule degrader platforms aimed at removing toxic protein aggregates implicated in neurodegenerative disease and designed to be central nervous system penetrant.
TRIMTECH Therapeutics, a biotech startup, has raised an additional £11m in a seed funding round, taking the total raised in the round to £35m. The extension will accelerate development of its proprietary small-molecule degrader platforms aimed at removing toxic protein aggregates implicated in neurodegenerative disease.
Why it matters
Neurodegenerative conditions such as Alzheimer’s and related disorders affect tens of millions globally and remain an area of high unmet need. TRIMTECH’s approach — using small molecules to selectively degrade toxic protein aggregates while preserving functional monomers — could open new therapeutic avenues where antibody or gene‑based approaches have struggled, particularly for indications that require molecules able to penetrate the central nervous system.
Inside the product
TRIMTECH’s technology is built on research into TRIM21, a relatively novel E3 ligase. The company says its TRIMTAC and TRIMGLUE series of degraders can target and degrade aggregates and oligomers while leaving monomeric proteins intact, a distinction that matters for cell function and safety. The assets are described as CNS penetrant, indicating designs intended to cross the blood‑brain barrier — a key challenge for neurodegeneration drug development.
The platform positions TRIMTECH in the broader protein‑degradation field, which has focused largely on a small set of E3 ligases until now. If the TRIM21 route works as described, it would expand the toolkit for small‑molecule degradation strategies aimed at large patient populations.
Who are the investors?
The £11m extension was led by Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and BGF. They join a syndicate of existing backers that includes Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, and Cambridge Enterprise Ventures.
Following the close, representatives from JJDC and BGF will join the TRIMTECH Therapeutics board as non‑executive directors. The presence of corporate venture arms such as JJDC, Pfizer Ventures and Eli Lilly signals continued pharmaceutical sector interest in early‑stage platforms that can diversify degrader chemistries.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Nicki Thompson, CEO at TRIMTECH Therapeutics, said:
We welcome JJDC and BGF as investors in our seed financing round and thank them for their support. This additional funding allows us to forge ahead with developing our portfolio of CNS penetrant degraders based on our unique platforms. TRIMTECH has incredibly strong scientific foundations combined with a world leading team augmented by a globally recognised investor syndicate – I'm excited to work with this exceptional group, to deliver the next phase of growth for the company.
The bigger picture
A £35m seed round (including this £11m extension) is sizeable for a UK biotech at this stage and reflects sustained appetite among pharma corporate venture funds and growth investors for new modalities targeting neurodegeneration. The deal underscores two broader trends: increasing investor interest in protein‑degradation technologies beyond the established E3 ligases, and a continuing flow of capital into UK and European biotech projects with clear translational paths to large patient populations.
The outcome will be watched by biotech investors across the UK and Europe as an indicator of how far small‑molecule degrader programmes can progress with seed‑stage backing and pharma strategic involvement.
They've invested in TRIMTECH Therapeutics
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 | ||||
 | ||||
 M Ventures( ) M Ventures is the strategic corporate venture capital fund of Merck, focusing on... Amsterdam, Netherlands | ||||
 Pfizer Ventures( ) Pfizer is a leading biopharmaceutical company focused on vaccines and treatments... NYC, US  | ||||
 Eli Lilly and Company( ) Indianapolis, US | ||||
 MP Healthcare Venture Management( ) Boston, US | ||||
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK